

Synonym

LAG3,CD223,FDC

Source

Human LAG-3 Protein, His Tag(LA3-H522a) is expressed from human 293 cells (HEK293). It contains AA Leu 23 - Leu 450 (Accession # [P18627-1](#) ).  
Predicted N-terminus: Leu 23

Molecular Characterization



This protein carries a polyhistidine tag at the C-terminus  
The protein has a calculated MW of 47.1 kDa. The protein migrates as 55-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin

Less than 0.01 EU per µg by the LAL method.

Purity

>95% as determined by SDS-PAGE.

Formulation

Lyophilized from 0.22 µm filtered solution in PBS, pH7.4 with trehalose as protectant.  
Contact us for customized product form or formulation.

Reconstitution


Please see Certificate of Analysis for specific instructions.  
*For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.*

Storage

For long term storage, the product should be stored at lyophilized state at -20°C or lower.  
*Please avoid repeated freeze-thaw cycles.*  
This product is stable after storage at:


- 20°C to -70°C for 12 months in lyophilized state;
- 70°C for 3 months under sterile conditions after reconstitution.

SDS-PAGE



Human LAG-3 Protein, His Tag on SDS-PAGE under reducing (R) condition.  
The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

Bioactivity-ELISA



Immobilized Anti-Human LAG3 MAb, Human IgG1 at 2 µg/mL (100 µL/well) can bind Human LAG-3 Protein, His Tag (Cat. No. LA3-H522a) with a linear range of 1-6 ng/mL (QC tested).

Background

Lymphocyte activation gene 3 protein (LAG3) is also known as CD antigen CD223 and protein FDC, which belongs to immunoglobulin (Ig) superfamily and contains 4 extracellular Ig-like domains. The LAG3 gene contains 8 exons. The sequence data, exon/intron organization, and chromosomal localization all indicate a close relationship of LAG3 to CD4. LAG3 /CD223 involved in lymphocyte activation. LAG3 /CD223 binds to HLA class-II antigens.

Clinical and Translational Updates

Please contact us via [TechSupport@acrobiosystems.com](mailto:TechSupport@acrobiosystems.com) if you have any question on this product.